HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 02-22-2009, 12:53 PM   #1
eric
Senior Member
 
Join Date: Sep 2005
Posts: 589
Genetech's upcoming plans with T-DM1

http://www.immunogen.com/wt/page/trastuzumab_DM1

Genentech has disclosed the following in terms of the T-DM1 development plans:
  • They plan to initiate a Phase III trial evaluating T-DM1 as a second-line treatment for HER2-positive metastatic breast cancer (MBC) in the first half of 2009. We have disclosed that the initiation of Phase III testing with T-DM1 triggers a milestone payment to ImmunoGen.
  • They have initiated a Phase II trial in August 2008 that evaluates T-DM1 as a third-line treatment for this cancer, another potential route to market for T-DM1.
  • They have initiated a Phase II trial comparing T-DM1, given as a single agent, to Herceptin (trastuzumab) plus Taxotere (docetaxel) as a first-line treatment for this cancer; and
  • They plan to start a Phase Ib trial in the first half of 2009 to evaluate T-DM1 given in combination with their pertuzumab compound (this one excites me for Caryn who responded VERY well to the DM1 but got thrown off because her body didn't handle the higher dose well)
eric is offline   Reply With Quote
 

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 04:40 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter